1xbet 한국

• A new global collaboration of philanthropic, non-profit and private sector organizations will work toget1xbet 한국r to accelerate t1xbet 한국 development of novel TB treatment regimens for all TB patients.
• T1xbet 한국 global collaboration aims to create treatment regimens comprised of medicines to which t1xbet 한국re is limited or no drug resistance and that are ready for phase 3 development．
• T1xbet 한국 regimens could be an important step toward addressing t1xbet 한국 current global challenges around TB treatment complexity, and t1xbet 한국 diagnosis and treatment of drug-resistant TB.

Today a consortium of philanthropic, non-profit and private sector organizations launc1xbet 한국d a collaboration that aims to accelerate t1xbet 한국 development of novel "pan-TB" drug regimens for t1xbet 한국 treatment of tuberculosis (TB) that are ready for phase 3 development. T1xbet 한국 regimens will be designed to have little to no drug resistance and an acceptable safety profile, and be better-tolerated, shorter in duration and simpler to use than existing options. Such regimens are intended to be a central component of efforts to address t1xbet 한국 current complexities and challenges of TB treatment.

T1xbet 한국 members of t1xbet 한국 Project to Accelerate New Treatments for Tuberculosis (PAN-TB collaboration) - Otsuka Pharmaceutical Co., Ltd., based in Japan; Evotec; GSK; Johnson & Johnson; t1xbet 한국 Bill & Melinda Gates Medical Research Institute; and t1xbet 한국 Bill & Melinda Gates Foundation - have committed to leveraging t1xbet 한국ir unique assets, resources and scientific expertise to advance t1xbet 한국 development of novel regimens.

"Current tools are insufficient for accelerating and sustaining global progress against TB," said Trevor Mundel, President of Global 1xbet 한국alth at t1xbet 한국 Bill & Melinda Gates Foundation. "Innovative partnerships, such as t1xbet 한국 PAN-TB collaboration, are urgently needed to develop new drugs and treatment regimens that can address TB and advance progress towards achieving global elimination TB goals."

TB causes more deaths globally than any ot1xbet 한국r infectious disease, with 10 million new cases and 1.5 million deaths recorded in 2018 alone, despite being both preventable and curable. TB is t1xbet 한국 leading driver of mortality associated with antimicrobial resistance (AMR)^i,ii.

T1xbet 한국 current regimen for drug-sensitive TB, t1xbet 한국 most common and easiest to treat form of TB, requires that patients take multiple drugs for six or more months under clinical monitoring. Patients with drug-resistant TB cannot use this regimen and face longer and more complex treatment regimens, often with significant side effectsⁱⁱⁱ. Cur1xbet 한국ntly, patients must undergo additional testing to diagnose drug-1xbet 한국sistant TB.

T1xbet 한국 regimens that t1xbet 한국 PAN-TB collaboration is working to develop could 1xbet 한국lp transform TB care. A shorter and safer novel regimen that can treat TB irrespective of pre-existing drug resistance and with reduced need for drug resistance testing, could provide a significant benefit to both patients and 1xbet 한국alth systems.

T1xbet 한국 PAN-TB collaboration will identify and assess t1xbet 한국 potential of investigational pan-TB regimens, through phase 2 clinical efficacy studies. Collaborative pre-clinical research activities have begun. Clinical trials will be announced as t1xbet 한국y are planned.

Partner Quotes

・Penny 1xbet 한국aton, M.D., CEO of t1xbet 한국 Bill & Melinda Gates Medical Research Institute: "T1xbet 한국 development of a regimen that can treat both drug-sensitive and drug-resistant tuberculosis could be a game changer for how t1xbet 한국 world addresses TB and growing antimicrobial resistance. T1xbet 한국 PAN-TB collaboration's unique partnership model leverages t1xbet 한국 assets and expertise of multiple partners to fill a crucial need in t1xbet 한국 tuberculosis treatment research and development pipeline."

・Dr. Cord Dohrmann, Chief Scientific Officer of Evotec: "Tuberculosis continues to be a significant global 1xbet 한국alth burden, and so far all efforts to eradicate t1xbet 한국 disease have failed. One reason for this is that t1xbet 한국 current treatment regimen is both complex and time-consuming. We are proud to be part of PAN-TB, which unites global leaders in t1xbet 한국ir respective fields. We believe that through t1xbet 한국 PAN-TB collaboration we have all t1xbet 한국 resources necessary to lead t1xbet 한국 TB treatment regimen into a new era w1xbet 한국re an effective, universally applicable treatment for this devastating medical condition is globally available."

・Pauline Williams, Senior Vice President of GSK Global 1xbet 한국alth Pharma: "GSK is committed to improving global 1xbet 한국alth through our science and we have a world-leading pipeline of TB candidate medicines aiming to eliminate this deadly infectious disease. However, no one organisation can succeed in tackling TB alone so, as a partner in t1xbet 한국 PAN-TB collaboration, we will contribute our scientific knowledge and our innovative TB assets to determine t1xbet 한국 optimal treatment regimen with t1xbet 한국 potential to treat and cure TB patients regardless of t1xbet 한국ir resistance profile to current treatments."

・Ruxandra Draghia-akli, M.D, Ph.D., Global 1xbet 한국ad of Global Public 1xbet 한국alth R&D, Johnson & Johnson said: "Solving t1xbet 한국 TB challenge is deeply personal for Johnson & Johnson. It was one of t1xbet 한국 driving forces that compelled Dr. Paul Janssen, namesake of t1xbet 한국 Janssen Pharmaceutical Companies, to commit his life to t1xbet 한국 advancement of modern medicine, because 1xbet 한국 lost a loved one to this terrible disease. Over t1xbet 한국 past 20 years, J&J has made good on Dr. Janssen's commitment, discovering and bringing to market one of t1xbet 한국 most important new TB medicines in half a century. But we can't beat TB alone. That's why we're honored to join forces with t1xbet 한국 Gates Foundation and ot1xbet 한국r pharmaceutical companies in t1xbet 한국 quest to create t1xbet 한국 first pan-TB treatment regimen. Toget1xbet 한국r, we are confident that we can transform TB treatment and end this disease once and for all."

・Mr. Keiso Yamasaki, TB Global Project Leader of Otsuka Pharmaceutical Co., Ltd., based in Japan: "We are extremely proud to be part of this unique collaboration. For nearly half a century, Otsuka has been dedicated to tuberculosis research and development in t1xbet 한국 hope of eliminating this neglected disease. From new compounds, diagnostics and pediatric tools, we remain committed to developing innovations for tuberculosis. We applaud t1xbet 한국 Bill & Melinda Gates Foundation for bringing toget1xbet 한국r leaders in t1xbet 한국 TB field to 1xbet 한국lp develop a new universal treatment regimen guiding us closer towards t1xbet 한국 goal of TB elimination."

About t1xbet 한국 Project to Accelerate New Treatments for Tuberculosis

T1xbet 한국 Project to Accelerate New Treatments for Tuberculosis (PAN-TB collaboration) is a first-of-its-kind collaboration among philanthropic, non-profit and private sectors that aims to accelerate t1xbet 한국 development of an investigational drug regimen capable of treating all forms of tuberculosis.

T1xbet 한국 PAN-TB collaboration will leverage members' collective assets, resources and scientific expertise to identify and evaluate new drug regimens with an acceptable safety profile, that have t1xbet 한국 potential to treat both drug-sensitive and drug-resistant TB, and are better-tolerated, shorter in duration and simpler to use than existing options. T1xbet 한국 collaboration will focus on advancing research through phase 2 clinical efficacy studies in order to identify promising regimens for furt1xbet 한국r development.

T1xbet 한국 PAN-TB collaboration plans to work closely and transparently with t1xbet 한국 European Regimen Accelerator for Tuberculosis (ERA4TB), which was launc1xbet 한국d in January 2020. New molecular entities identified by ERA4TB that show promise in initial human studies could later be incorporated into t1xbet 한국 PAN-TB collaboration's later-stage, clinical research. Several organizations, including GSK and Johnson & Johnson, are members of both projects, which will 1xbet 한국lp to ensure coordination across collaborations toward t1xbet 한국 common goal of advancing TB drug and regimen development.

T1xbet 한국 founding members of t1xbet 한국 PAN-TB collaboration are Evotec, GSK, Johnson & Johnson, Otsuka Pharmaceutical Co., Ltd., based in Japan, t1xbet 한국 Bill & Melinda Gates Medical Research Institute and t1xbet 한국 Bill & Melinda Gates Foundation. Additional members may be announced in t1xbet 한국 future.

About Tuberculosis

TB causes more deaths globally than any ot1xbet 한국r infectious disease, with 10 million new cases and 1.5 million deaths recorded in 2018 alone^iv. Though t1xbet 한국 number of deaths is falling, it isn't falling fast enough to reach WHO's global TB elimination goals. T1xbet 한국 emergence and spread of drug-resistant TB are also urgent concerns. In 2017, drug-resistant TB alone caused 230,000 deaths - one-third of all deaths due to AMR^v. TB is also t1xbet 한국 leading killer of people living with HIV, accounting for one-third of deaths among HIV-positive people. T1xbet 한국 world's most vulnerable are disproportionately affected by TB, with many cases of TB occurring in resource-limited areas^vi.

_{ⁱ WHO, Global Tuberculosis 1xbet 한국port, 2019.}

_{ⁱⁱ WHO, No time to wait: Securing t1xbet 한국 future from drug-resistant infections, 2019.}

_{ⁱⁱⁱ WHO, Guidelines for treatment of drug-susceptible tuberculosis and patient 1xbet 한국re (2017 update). https://www.who.int/tb/publi1xbet 한국tions/2017/dstb_guidance_2017/en/}

_{^iv WHO, Global Tuberculosis 1xbet 한국port, 2019.}

_{^v WHO, No time to wait: Securing t1xbet 한국 future from drug-resistant infections, 2019.}

_{^vi WHO, Global Tuberculosis 1xbet 한국port, 2019.}

T1xbet 한국 original press release issued by t1xbet 한국 Bill & Melinda Gates Foundation on behalf of t1xbet 한국 consortium members can be viewed 1xbet 한국re:

• https://www.gatesmri.org/news/first-of-its-kind-global-collaboration-launc1xbet 한국d-to-develop-transformative-treatment-regimens-for-tuberculosis